



Endo Announces Launch of Generic Version of Valcyte®

November 20, 2014

DUBLIN, Nov. 20, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that its Qualitest subsidiary has launched a generic version of Hoffmann-La Roche, Inc.'s Valcyte® (Valganciclovir Tablets USP, 450 mg).

"We are pleased to announce the commercial availability of generic Valcyte," said Rajiv De Silva, president and chief executive officer of Endo. "Our generic product, as the first generic version of Valcyte available in the U.S. plays an important role in providing patients with a more affordable treatment option."

For the 12 months ending September 30, 2014, Valcyte® had total U.S. sales of approximately \$440 million, according to IMS Health data.

About Endo:

Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic pharmaceutical, over the counter medications and medical device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

SOURCE Endo International plc

Investors/Media: Blaine Davis, +353-1-268-2001, (484) 216-7158; Investors: Jonathan Neely, (484) 216-6645; Media: Heather Zoumas Lubeski, (484) 216-6829